- Home
- OTLY vs CAPR Comparison
OTLY vs CAPR Comparison
Compare OTLY & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- CAPR
- Stock Information
- Founded
- OTLY 1994
- CAPR 2005
- Country
- OTLY Sweden
- CAPR United States
- Employees
- OTLY N/A
- CAPR N/A
- Industry
- OTLY Packaged Foods
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OTLY Consumer Staples
- CAPR Health Care
- Exchange
- OTLY Nasdaq
- CAPR Nasdaq
- Market Cap
- OTLY 303.5M
- CAPR 324.6M
- IPO Year
- OTLY 2021
- CAPR N/A
- Fundamental
- Price
- OTLY $17.95
- CAPR $6.36
- Analyst Decision
- OTLY Buy
- CAPR Strong Buy
- Analyst Count
- OTLY 5
- CAPR 8
- Target Price
- OTLY $19.25
- CAPR $24.75
- AVG Volume (30 Days)
- OTLY 163.4K
- CAPR 1.2M
- Earning Date
- OTLY 11-06-2025
- CAPR 11-12-2025
- Dividend Yield
- OTLY N/A
- CAPR N/A
- EPS Growth
- OTLY N/A
- CAPR N/A
- EPS
- OTLY N/A
- CAPR N/A
- Revenue
- OTLY $828,200,000.00
- CAPR $13,392,150.00
- Revenue This Year
- OTLY $3.83
- CAPR N/A
- Revenue Next Year
- OTLY $4.51
- CAPR $6,061.53
- P/E Ratio
- OTLY N/A
- CAPR N/A
- Revenue Growth
- OTLY 4.43
- CAPR N/A
- 52 Week Low
- OTLY $6.00
- CAPR $4.05
- 52 Week High
- OTLY $20.80
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- OTLY 58.03
- CAPR 42.32
- Support Level
- OTLY $16.50
- CAPR $6.05
- Resistance Level
- OTLY $17.75
- CAPR $6.62
- Average True Range (ATR)
- OTLY 0.83
- CAPR 0.39
- MACD
- OTLY -0.12
- CAPR 0.05
- Stochastic Oscillator
- OTLY 65.64
- CAPR 47.89
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.